文献速递腹部介入MR

基线三维表观扩散系数优于二维表观扩散系数预测结直肠癌肝转移患者治疗反应

Baseline 3D-ADC outperforms 2D-ADC in predicting response to treatment in patients with colorectal liver metastases.
PubMed 文献 · Eur Radiol · 2019-06-17

回顾性纳入68例结直肠癌肝转移患者,于治疗前测量病灶三维表观扩散系数(3D-ADC)与二维表观扩散系数(2D-ADC),以RECIST 1.1评估短期治疗反应。3D-ADC预测治疗反应的AUC为0.86,优于2D-ADC的0.71(P<0.001);以ADC第10百分位1006×10⁻⁶ mm²/s为阈值,敏感度77.4%、特异度91.3%。

要点

  • 基线3D-ADC预测肝转移瘤短期治疗反应AUC为0.86,优于2D-ADC的0.71(P<0.001)。
  • 3D-ADC预测90Y放射栓塞的AUC为0.90,TACE为0.88,全身化疗为0.77(P<0.01)。
  • ADC第10百分位1006×10⁻⁶ mm²/s为最佳预测阈值,敏感度77.4%、特异度91.3%。

核心结论

  • 基线3D-ADC是预测结直肠癌肝转移短期部分治疗反应的高特异度生物标志物,且预测效能优于2D-ADC。

研究设计与样本

  • 回顾性研究,复习2008—2015年546例结直肠癌肝转移患者肝脏MR图像,68例符合纳入标准;患者接受全身化疗(n=17)、肝动脉化疗栓塞(TACE,n=34)或90Y放射栓塞(n=17);采用原型软件计算病灶基线3D-ADC(容积法),以RECIST 1.1评估短期治疗反应,并比较3D-ADC与2D-ADC(基于ROI)的预测效能。

诊断标准与关键数值

  • 部分治疗反应定义为肿瘤最大横径较基线缩小至少30%,35.3%的患者出现部分反应:全身化疗41.2%、TACE 32.4%、90Y放射栓塞35.3%(P=0.82)。3D-ADC预测治疗反应的AUC在90Y放射栓塞患者为0.90、TACE患者为0.88、全身化疗患者为0.77(P<0.01)。最佳预测阈值为ADC第10百分位1006×10⁻⁶ mm²/s,敏感度77.4%、特异度91.3%。3D-ADC预测治疗反应的AUC为0.86,优于2D-ADC的0.71(P<0.001)。

临床应用与阅片要点

  • 阅片时可于治疗前测量肝转移灶容积3D-ADC,并关注ADC第10百分位1006×10⁻⁶ mm²/s这一阈值;3D-ADC对90Y放射栓塞的预测效能高于全身化疗/TACE。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To examine the value of baseline 3D-ADC and to predict short-term response to treatment in patients with hepatic colorectal metastases (CLMs).

METHODS: Liver MR images of 546 patients with CLMs (2008-2015) were reviewed retrospectively and 68 patients fulfilled inclusion criteria. Patients had received systemic chemotherapy (n = 17), hepatic trans-arterial chemoembolization or TACE (n = 34), and 90Y radioembolization (n = 17). Baseline (pre-treatment) 3D-ADC (volumetric) of metastatic lesions was calculated employing prototype software. RECIST 1.1 was used to assess short-term response to treatment. Prediction of response to treatment by baseline 3D-ADC and 2D-ADC (ROI-based) was also compared in all patients.

RESULTS: Partial response to treatment (minimum 30% decrease in tumor largest transverse diameter) was seen in 35.3% of patients; 41.2% with systemic chemotherapy, 32.4% with TACE, and 35.3% with 90Y radioembolization (p = 0.82). Median baseline 3D-ADC was significantly lower in responding than in nonresponding lesions. Area under the curve (AUC) of 3D-ADC was 0.90 in 90Y radioembolization patients, 0.88 in TACE patients, and 0.77 in systemic chemotherapy patients (p < 0.01). Optimal prediction was observed with the 10th percentile of ADC (1006 × 10-6 mm2/s), yielding sensitivity and specificity of 77.4% and 91.3%, respectively. 3D-ADC outperformed 2D-ADC in predicting response to treatment (AUC; 0.86 vs. 0.71; p < 0.001).

CONCLUSION: Baseline 3D-ADC is a highly specific biomarker in predicting partial short-term response to treatment in hepatic CLMs.

KEY POINTS: • Baseline 3D-ADC is a highly specific biomarker in predicting response to different treatments in hepatic CLMs. • The prediction level of baseline ADC is better for90Y radioembolization than for systemic chemotherapy/TACE in hepatic CLMs. • 3D-ADC outperforms 2D-ADC in predicting short-term response to treatment in hepatic CLMs.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Fouladi DF, Zarghampour M, Pandey P, et al. Baseline 3D-ADC outperforms 2D-ADC in predicting response to treatment in patients with colorectal liver metastases. Eur Radiol. 2019. PMID: 31209620. doi:10.1007/s00330-019-06289-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。